App-Quantinova.ai

Time from referral to definitive treatment in Cushing’s syndrome

Amy Coulden - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cushing's syndrome

N/A

Multiplex serum steroid profiling using liquid chromatography mass spectrometry with post column infusion ammonium fluoride

Lina Schiffer - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Outcome of COVID-19 infections in patients with adrenal insufficiency

Hanna Nowotny - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Addison's disease

N/A

Bilateral adrenal haemorrhage due to e.coli sepsis precipitating adrenal crisis in pregnancy: a case report

Nabeel Ahmed - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Addison's disease

Hydrocortisone

Development of a novel treatment strategy which involves thermal ablation of adrenal adenomas using electromagnetic energy

Richard Farnan - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Evaluation of a tertiary centre specialist adrenal MDT: The first 900 patients

Louisa Child - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adrenal carcinoma

Dexamethasone

Progression of atherosclerosis after the menopause and the role of circulating Amyloid Beta 1-40

Irene Lambrinoudaki - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

A single dose of Neutrophil Elastase inhibitor Elafin does not alter CBG cleavage during post-surgical stress in humans in vivo

Luke D Boyle - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Elaszym

A retrospective evaluation of the utility of overnight dexamethasone suppression tests in over 500 patients evaluated for hypercortisolism

Rebecca Sagar - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cushing's syndrome

Dexamethasone

Objective markers and new indicators in adrenal insufficiency- findings from the omni-aid study comparing hydrocortisone and prednisolone replacement therapy

Sirazum Choudhury - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Addison's disease

Hydrocortisone

Challenges and anxiety of fluctuating normal to mild/moderate elevations of urinary catecholamines and metanephrines in clinical practice

Bonnie Grant - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Phenoxybenzamine

Lower than recommended doses of cinacalcet are effective and well tolerated in the control of hypercalcaemia of primary hyperparathyroidism

Nyein Nge Nge - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Primary hyperparathyroidism

Cinacalcet hydrochloride

Phosphate-mediated inhibition of calcium-sensing receptor expressed endogenously in the thyroidal TT cell-line

Khaleda Alghamdi - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Secondary hyperparathyroidism

Parathyroid hormone

The international x-linked hypophosphataemia (xlh) registry: overview of the dataset

Sandro Giannini - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

X-linked hypophosphataemia

N/A

Case report: an unusual presentation of hypercalcaemia in pregnancy

Scott Williams - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary hyperparathyroidism

Parathyroid hormone

Serum 25-hydroxyvitamin D (25(OH)D) levels in Pregnant women with gestational diabetes mellitus

Edward Jude - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Gestational Diabetes

Ergocalciferol

A case of severe hypercalcaemia secondary to primary hyperparathyroidism responding to steroids

Susan Mathew - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Primary hyperparathyroidism

Zolendronic acid

Hypoglycaemia associated with variable rate intravenous insulin infusion and concurrent administration of balanced electrolyte solution: A single hospital experience

Vinit Shah - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Sochlor

Comparison of hyperphagia and problem behaviors in participants with prader-willi syndrome (PWS) receiving diazoxide choline extended-release (DCCR) with matched participants in PATH for PWS (PfPWS)

Evelien Gevers - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Prader-willi syndrome

Diazoxide

Non-invasive quantification of pancreatic islet beta-cell function in people with type 1 diabetes mellitus

Shruti Joshi - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Filters

45280 Abstracts